| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $102,294,589 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA277464 | Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life | 002 | 2 | NIH | 6/11/2025 | $20,686 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA277464 | Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life | 001 | 2 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA277464 | Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life | 000 | 2 | NIH | 12/27/2024 | $186,183 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA272717 | Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer | 001 | 3 | NIH | 5/22/2025 | $54,226 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 000 | 3 | NIH | 3/20/2025 | $509,034 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 001 | 5 | NIH | 5/22/2025 | $52,119 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 001 | 5 | NIH | 5/28/2025 | $62,218 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 5 | NIH | 2/19/2025 | $559,979 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 5 | NIH | 2/25/2025 | $688,546 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 001 | 5 | NIH | 4/29/2025 | $24,899 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012203 | New approaches for leveraging single-cell data to identify disease-critical genes and gene sets | 000 | 5 | NIH | 3/6/2025 | $224,101 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 001 | 4 | NIH | 5/22/2025 | $45,703 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 4 | NIH | 3/20/2025 | $411,339 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 001 | 5 | NIH | 5/22/2025 | $46,574 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258886 | Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinoma | 000 | 5 | NIH | 3/5/2025 | $419,169 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 3 | NIH | 2/28/2025 | $268,826 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248289 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | 000 | 6 | NIH | 3/3/2025 | $545,622 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA252633 | Behavioral Activation for Depression in Older Adult Cancer Survivors: Pilot Randomized Control Trial and Implementation Outcomes | 000 | 5 | NIH | 2/28/2025 | $174,699 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 1 | NIH | 2/24/2025 | $205,700 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 001 | 2 | NIH | 6/17/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 2 | NIH | 2/18/2025 | $135,224 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 000 | 1 | NIH | 3/11/2025 | $700,611 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297030 | Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | 000 | 1 | NIH | 2/25/2025 | $145,336 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK132518 | Control of Intestinal Epithelial Function through Lymphatic-Intestinal Stem Cell Communication | 001 | 4 | NIH | 2/25/2025 | $167,617 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 002 | 3 | NIH | 5/22/2025 | $65,164 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 001 | 3 | NIH | 2/28/2025 | $586,485 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 001 | 5 | NIH | 5/22/2025 | $44,073 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 000 | 5 | NIH | 2/14/2025 | $396,645 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 001 | 4 | NIH | 4/25/2025 | $72,522 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01MD016908 | Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity) | 000 | 4 | NIH | 2/18/2025 | $652,690 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 000 | 2 | NIH | 3/13/2025 | $626,533 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA300788 | Inflammatory Signaling in the Leptomeninges | 000 | 1 | NIH | 3/11/2025 | $730,398 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA245471 | Investigating the Role of Cell Plasticity in Malignant Transformation | 000 | 6 | NIH | 2/18/2025 | $106,030 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 1 | NIH | 1/30/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 001 | 4 | NIH | 4/28/2025 | $1,101,453 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA271287 | Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | 002 | 4 | NIH | 5/28/2025 | $122,908 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 001 | 6 | NIH | 5/30/2025 | $28,481 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA238317 | Lipid programs in melanocyte transformation | 000 | 6 | NIH | 3/3/2025 | $256,330 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F99CA294267 | Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells. | 000 | 1 | NIH | 1/28/2025 | $3,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AR068128 | Mechanisms and Function of Myonuclear Positioning | 000 | 10 | NIH | 1/28/2025 | $547,414 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA273923 | Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) Trial | 000 | 3 | NIH | 5/21/2025 | $580,036 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA263967 | Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | 000 | 5 | NIH | 5/8/2025 | $727,406 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 001 | 6 | NIH | 5/28/2025 | $37,559 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 000 | 6 | NIH | 3/12/2025 | $338,027 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA276804 | Targeting Pancreatic Cancer Senescence with ImmunoPET | 000 | 2 | NIH | 2/28/2025 | $148,282 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA280657 | Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer | 000 | 3 | NIH | 2/13/2025 | $654,500 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA244911 | Targeting stem-like cells and their niche in pancreatic cancer | 000 | 6 | NIH | 3/14/2025 | $441,764 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 001 | 2 | NIH | 5/22/2025 | $157,035 |
|
